Skip to main content
OpenTrials
Completed

NCT Number: NCT02891356

Bone Mass Changes in Anorexia Nervosa Patient Followed During 4 Years

The mechanism of bone loss in anorexia nervosa is complex. Marrow adipose tissue seems to play a role in the regulation of bone metabolism. Adipocytes secrete cytokines and adipokines that either stimulate or inhibit adjacent osteoblasts. This study consist to explore the relationship in anorexia nervosa patients with change in bone mineral density and adipokines like leptin, adiponectin and Préf-1 Bone mineral densities will be measure in 180 anorexia nervosa patients at inclusion and every two years during 6 years.It is assessed blood and urinary calcium and phosphate levels, bone remodelling markers and adipokines (leptin, adiponectin and Préf-1)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anorexia Nervosa Bone Diseases Bone Diseases, Metabolic Feeding and Eating Disorders Mental Disorders Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases Osteoporosis

Age range

18 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

Hôpital Roger Salengro, CHRU de Lille

Lille, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • anorexia patient defined by DSM IV diagnostic criteria

Exclusion criteria

  • patient with other psychiatric disease
  • patient with other a metabolic bone disease

Treatment and study plan

DEXA

Device

The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck

Primary outcomes

  1. Bone mineral density by Dual Energy X-ray Absorptiometry (DEXA)

    Time frame: 4 years

    measured the evolution of the bone mineral density in 180 anorexia nervosa patients and the relationship with this change and adipokine

Secondary outcomes

  1. Incidence of osteoporotic fractures

    Time frame: at 2,4 and 6 years

  2. Adiponectin plasma concentration by ELISA

    Time frame: at 2,4 and 6 years

    measurement of circulating biological factors predicative of changes in BMD

  3. Interleukin-7 plasma concentration by ELISA

    Time frame: at 2,4 and 6 years

    measurement of circulating biological factors predicative of changes in BMD

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Official study title

Bone Mass Changes in Anorexia Nervosa Patient Followed During 4 Years and Relationship Between Bone Loss and Adipokines.

Acronym: AMOS

Important dates

Study start
2013
Primary completion
2022
Study completion
2022
First posted
Sep 7, 2016
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.